Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

AKM Claessens; Monique Bos; M Lopez-Yurda; JM Bouma; JM Rademaker-Lakhai; AH Honkoop; H Graaf; E van Druten; LJC van Warmerdam; MJC van der Sangen; VCG Tjan-Heijnen; FLG Erdkamp

doi:10.1007/s10549-018-4906-8

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

AKM Claessens, Monique Bos, M Lopez-Yurda, JM Bouma, JM Rademaker-Lakhai, AH Honkoop, H Graaf, E van Druten, LJC van Warmerdam, MJC van der Sangen, VCG Tjan-Heijnen, FLG Erdkamp

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

15 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	413-423
Number of pages	11
Journal	Breast Cancer Research and Treatment
Volume	172
Issue number	2
DOIs	https://doi.org/10.1007/s10549-018-4906-8
Publication status	Published - 2018

Research programs

EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-018-4906-8

http://hdl.handle.net/1765/109962

Cite this

Claessens, AKM., Bos, M., Lopez-Yurda, M., Bouma, JM., Rademaker-Lakhai, JM., Honkoop, AH., Graaf, H., van Druten, E., van Warmerdam, LJC., van der Sangen, MJC., Tjan-Heijnen, VCG., & Erdkamp, FLG. (2018). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Research and Treatment, 172(2), 413-423. https://doi.org/10.1007/s10549-018-4906-8

@article{a9297b7f5aa24ff39273585e71484aac,

title = "Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)",

author = "AKM Claessens and Monique Bos and M Lopez-Yurda and JM Bouma and JM Rademaker-Lakhai and AH Honkoop and H Graaf and {van Druten}, E and {van Warmerdam}, LJC and {van der Sangen}, MJC and VCG Tjan-Heijnen and FLG Erdkamp",

year = "2018",

doi = "10.1007/s10549-018-4906-8",

language = "Undefined/Unknown",

volume = "172",

pages = "413--423",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "2",

}

Claessens, AKM, Bos, M, Lopez-Yurda, M, Bouma, JM, Rademaker-Lakhai, JM, Honkoop, AH, Graaf, H, van Druten, E, van Warmerdam, LJC, van der Sangen, MJC, Tjan-Heijnen, VCG & Erdkamp, FLG 2018, 'Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 413-423. https://doi.org/10.1007/s10549-018-4906-8

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). / Claessens, AKM; Bos, Monique; Lopez-Yurda, M et al.
In: Breast Cancer Research and Treatment, Vol. 172, No. 2, 2018, p. 413-423.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

AU - Claessens, AKM

AU - Bos, Monique

AU - Lopez-Yurda, M

AU - Bouma, JM

AU - Rademaker-Lakhai, JM

AU - Honkoop, AH

AU - Graaf, H

AU - van Druten, E

AU - van Warmerdam, LJC

AU - van der Sangen, MJC

AU - Tjan-Heijnen, VCG

AU - Erdkamp, FLG

PY - 2018

Y1 - 2018

U2 - 10.1007/s10549-018-4906-8

DO - 10.1007/s10549-018-4906-8

M3 - Article

C2 - 30121808

SN - 0167-6806

VL - 172

SP - 413

EP - 423

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -